ArticleBMC public health2026
Disparities in breast cancer screening, stage at diagnosis, and treatment in Brazil: a warning of the need to change public policies.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most prevalent form of cancer in Brazilian women, contributing significantly to cancer-related mortality, particularly when diagnosed at advanced stages.
methodsThis ecological, temporal series study evaluated breast cancer mammography screening rate, clinical staging, and the time from diagnosis to treatment initiation in women of 40–49, 50–69 and [Formula: see text]70 years of age in Brazil, its geographical regions, and states between 2013 and 2022. The data were extracted from databases of the Unified Health System (DATASUS).
resultsThere was a decreasing trend in mammography screening rate for the 40-49-year age group between 2013 and 2020 (Annual Percentual Change- APC= -10.79; p < 0.001), and stability in 2020–2022. Rates for the 50-69-year group remained stable, while fell for women [Formula: see text]70 years of age (APC= -6.27; p < 0.001) between 2013 and 2022. Cases of advanced stages at diagnosis tended to increase in all age groups: 40–49 (APC=1.71; p < 0.001), 50–69 (APC = 1.43; p < 0.001) and [Formula: see text]70 years (APC = 1.82; p = 0.001). The mammography screening rate was low for all the age groups and all geographical regions, with lower rates found for the 40–49 and [Formula: see text]70-year age groups. The poorest screening rates were seen in the regions North, Northeast and Midwest, revealing regional disparities. The proportion of cases diagnosed at advanced stages (III/IV) increased, particularly in 40–49 and [Formula: see text]70-year age groups. Time from diagnosis to treatment initiation exceeded 60 days in >50% of cases in all age groups, with an increasing trend in women of 50–69 (APC = 1.27; p < 0.001) and [Formula: see text]70 years of age (APC=1.83; p < 0.001).
conclusionsThis study highlights the urgent need for public policies to increase BC mammography screening rate beyond the 50-69-year age group, and to guarantee equitable access to early diagnosis and timely treatment, particularly in less affluent areas. Dealing with these disparities is crucial to improving BC outcomes in Brazil, positively influencing clinical stage at diagnosis, treatment efficacy, and ultimately, survival and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.